Onto Innovation, OSI Systems, NVE, Nano Dimension, Biodexa Pharmaceuticals, Clene, and Virpax Pharmaceuticals are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of publicly traded companies whose core business involves researching, developing or commercializing technologies that manipulate matter at the atomic or molecular scale. These firms may operate across sectors such as electronics, healthcare, energy and materials science, leveraging nanoscale innovations to create new products or enhance existing ones. Investors buy nanotechnology stocks to gain exposure to the growth potential—and risks—of businesses pioneering breakthroughs in molecular‐level engineering. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
Onto Innovation (ONTO)
Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.
Shares of NYSE ONTO traded down $1.19 during trading hours on Friday, reaching $95.78. The stock had a trading volume of 1,755,612 shares, compared to its average volume of 974,411. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of 21.67, a P/E/G ratio of 0.63 and a beta of 1.45. The business's fifty day moving average price is $105.66 and its two-hundred day moving average price is $143.52. Onto Innovation has a 52-week low of $85.88 and a 52-week high of $238.93.
Read Our Latest Research Report on ONTO
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
Shares of NASDAQ OSIS traded down $3.41 during trading hours on Friday, reaching $214.95. The stock had a trading volume of 480,137 shares, compared to its average volume of 202,546. The company has a current ratio of 2.11, a quick ratio of 1.38 and a debt-to-equity ratio of 0.53. The firm has a market cap of $3.61 billion, a price-to-earnings ratio of 26.15, a P/E/G ratio of 1.99 and a beta of 1.28. The business's fifty day moving average price is $217.77 and its two-hundred day moving average price is $197.40. OSI Systems has a 52-week low of $129.18 and a 52-week high of $241.64.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
Shares of NASDAQ NVEC traded down $0.43 during trading hours on Friday, reaching $69.50. The stock had a trading volume of 122,456 shares, compared to its average volume of 28,108. The firm has a market cap of $336.38 million, a price-to-earnings ratio of 22.35 and a beta of 1.15. The business's fifty day moving average price is $66.70 and its two-hundred day moving average price is $70.28. NVE has a 52-week low of $51.50 and a 52-week high of $89.98.
Read Our Latest Research Report on NVEC
Nano Dimension (NNDM)
Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.
Shares of NASDAQ NNDM remained flat at $1.39 during trading hours on Friday. The company had a trading volume of 2,054,839 shares, compared to its average volume of 1,642,894. The firm has a market cap of $302.02 million, a price-to-earnings ratio of -3.47 and a beta of 1.13. The company has a 50-day moving average price of $1.54 and a two-hundred day moving average price of $1.98. Nano Dimension has a 12-month low of $1.34 and a 12-month high of $2.74.
Read Our Latest Research Report on NNDM
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Biodexa Pharmaceuticals stock traded down $0.16 during mid-day trading on Friday, reaching $0.87. 1,720,851 shares of the company were exchanged, compared to its average volume of 1,089,217. The business has a fifty day moving average of $1.27 and a 200 day moving average of $2.72. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.01. Biodexa Pharmaceuticals has a 12-month low of $0.78 and a 12-month high of $41.50.
Read Our Latest Research Report on BDRX
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Clene stock traded down $0.09 during mid-day trading on Friday, reaching $4.28. 64,162 shares of the company were exchanged, compared to its average volume of 89,744. The business has a fifty day moving average of $3.24 and a 200 day moving average of $4.00. The firm has a market cap of $38.43 million, a P/E ratio of -1.06 and a beta of 0.49. Clene has a 12-month low of $2.28 and a 12-month high of $8.20.
Read Our Latest Research Report on CLNN
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Virpax Pharmaceuticals stock traded down $0.03 during mid-day trading on Friday, reaching $0.25. 17,533 shares of the company were exchanged, compared to its average volume of 201,263. The business has a fifty day moving average of $0.25 and a 200 day moving average of $4.10. Virpax Pharmaceuticals has a 12-month low of $0.13 and a 12-month high of $84.75.
Read Our Latest Research Report on VRPX
See Also
Before you consider Onto Innovation, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Onto Innovation wasn't on the list.
While Onto Innovation currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
